{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/atrial-fibrillation/prescribing-information/digoxin/","result":{"pageContext":{"chapter":{"id":"037e75e8-454f-5dcd-a0b8-3e9ff5a5b309","slug":"digoxin","fullItemName":"Digoxin","depth":2,"htmlHeader":"<!-- begin field 9baffd42-720f-47ce-80fa-ee0007669b87 --><h2>Digoxin</h2><!-- end field 9baffd42-720f-47ce-80fa-ee0007669b87 -->","summary":"","htmlStringContent":"<!-- begin item a2c7bb06-5ad9-46b2-b347-e486bfe0c94c --><!-- end item a2c7bb06-5ad9-46b2-b347-e486bfe0c94c -->","topic":{"id":"c61747eb-a307-5da3-9878-9e952f2e1246","topicId":"e42fc175-7ae7-44c7-b7ef-b58a14733e7e","topicName":"Atrial fibrillation","slug":"atrial-fibrillation","lastRevised":"Last revised in October 2020","chapters":[{"id":"15747365-1cc2-550f-ad60-639db7df4ff0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9ced6fef-0141-5375-b1c4-37d2756e7678","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"75cb268e-28e7-51c1-87dd-0a86fbc0616b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"1390db2e-6367-52cb-9af5-792d2e4d9310","slug":"changes","fullItemName":"Changes"},{"id":"f65a3e88-8f57-5c09-867a-ba88262e838c","slug":"update","fullItemName":"Update"}]},{"id":"16591b01-3ee5-5b14-a7e2-7a5226294933","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f3967a51-562c-5a5b-b55a-02dd39bfcbe9","slug":"goals","fullItemName":"Goals"},{"id":"5a66a5f8-9497-5664-abc1-d16cfe63bdd4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ca3b265-f279-56a1-94f0-c0e96dbeaaff","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8bf96582-45d8-507c-9772-4c1092b4bd6a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"992b55c8-2134-5283-b0f7-34608af53bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"677bafba-be09-57b3-a169-096ee3aa3fa1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6e491b1-6724-5c59-b127-fc29812ea52f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"dab901c7-1cc0-5253-a4e0-e5b5bc04ba5e","slug":"definition","fullItemName":"Definition"},{"id":"39c5efdc-48cc-5b0a-85d7-f7da2de67a25","slug":"causes","fullItemName":"Causes"},{"id":"211e1811-bd20-5cfb-b7b9-c06c3fd223a3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"96a3b3f8-183a-52b6-9909-a81f0fd999dd","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"fc0c1acd-3cda-53a5-85ae-be117589c6bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0a1e6d67-1c9c-5ea9-a30c-006e32e641c7","slug":"diagnosis-of-atrial-fibrillation","fullItemName":"Diagnosis of atrial fibrillation"}]},{"id":"42efe54e-8ff7-5283-ad5f-7dabdd2dcdff","fullItemName":"Management","slug":"management","subChapters":[{"id":"a955511a-8fbf-5bf9-aa82-b0e634a6325b","slug":"management-of-af","fullItemName":"Scenario: Management of AF"}]},{"id":"c2a59ca9-6ff7-533b-912e-d7ba0cc5fcb9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2c20504-f7cb-54cc-adc0-c0cb70ec0ccb","slug":"beta-blockers-except-sotalol","fullItemName":"Beta-blockers (except sotalol)"},{"id":"d02a47f9-0498-503c-9cb1-0c3f89766d4f","slug":"diltiazem-verapamil","fullItemName":"Diltiazem and verapamil"},{"id":"037e75e8-454f-5dcd-a0b8-3e9ff5a5b309","slug":"digoxin","fullItemName":"Digoxin"},{"id":"c0c53c1d-4cd9-5e70-8a01-3d5f59d213cb","slug":"anticoagulants","fullItemName":"Anticoagulants"},{"id":"49e47ec1-0743-51db-a133-a2eed45d0eb0","slug":"aspirin-clopidogrel","fullItemName":"Aspirin and clopidogrel"},{"id":"5cb461d2-9502-5698-a467-30edd459c1b3","slug":"amiodarone-not-initiated-in-primary-care","fullItemName":"Amiodarone - not initiated in primary care"},{"id":"0fae1520-f160-57a2-af90-5b46bb20bdf5","slug":"sotalol-not-initiated-in-primary-care","fullItemName":"Sotalol - not initiated in primary care"}]},{"id":"1048ec97-41b1-5f93-a54d-1f58a8a56528","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5fff0dc2-1e01-590e-a159-76736c6a2ac0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b4497d2f-172b-54a5-99c6-5cd92c8469ba","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d1d9c4e5-758a-5a99-93e3-4d2099a68d60","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0b86c2fd-54d8-569a-a8a8-ccadd53c17a0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e7ea1b2f-6198-53f7-b4f8-681296a03562","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3a114d83-bf8b-5507-b946-6af4f46c529e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5bbaf83e-cca2-55f4-a4c9-e6b808387a89","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c2a59ca9-6ff7-533b-912e-d7ba0cc5fcb9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"abf09aa9-fd3c-5ebb-b5d1-bd3b3c782106","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field ca88420b-dacc-44ab-a6f7-d91b8991bfd6 --><h3>What are the contraindications and cautions of digoxin?</h3><!-- end field ca88420b-dacc-44ab-a6f7-d91b8991bfd6 -->","summary":"","htmlStringContent":"<!-- begin item 16bd308f-93cf-4884-b771-c205b4936a30 --><!-- begin field 67c92078-d901-443c-a183-ce07467dc19f --><ul><li><strong>Do not prescribe digoxin to people with</strong><strong>:</strong><ul><li>Some supraventricular arrhythmias (such as Wolff–Parkinson–White syndrome).</li><li>Arrhythmias caused by previous use of digoxin or another cardiac glycoside.</li><li>Heart conduction problems (such as intermittent complete heart block or atrioventricular heart block).</li><li>Ventricular tachycardia or ventricular fibrillation.</li><li>Hypertrophic obstructive cardiomyopathy, unless there is concomitant atrial fibrillation and heart failure (but use with caution in this case).</li></ul></li><li><strong>Prescribe digoxin with caution to</strong><strong>:</strong><ul><li>People with:<ul><li>Recent myocardial infarction.</li><li>Sick sinus syndrome.</li><li>Thyroid disease.</li><li>Severe respiratory disease.</li><li>Hypokalaemia, hypomagnesaemia, hypercalcaemia, and hypoxia (risk of digitalis toxicity).</li><li>Renal impairment — reduce dose and monitor plasma-digoxin concentration; toxicity increased by electrolyte disturbances.</li></ul></li><li>Elderly people — reduce dose in the elderly.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2019d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 67c92078-d901-443c-a183-ce07467dc19f --><!-- end item 16bd308f-93cf-4884-b771-c205b4936a30 -->","subChapters":[]},{"id":"81cd38d3-23c5-50c9-9536-c9792e289569","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 4445754f-01f7-445b-8621-053ac1730a92 --><h3>What dose of digoxin should I prescribe, and how should the dose be titrated?</h3><!-- end field 4445754f-01f7-445b-8621-053ac1730a92 -->","summary":"","htmlStringContent":"<!-- begin item dc9bf870-e369-4c76-8789-de0e97a0cc71 --><!-- begin field d08809d9-6d92-4ee2-9059-6c423344da91 --><ul><li>Prescribe a loading dose of 250 micrograms to 750 micrograms a day for 7 days, followed by a maintenance dose. A clinical response is usually seen within 1 week.<ul><li><strong>Seek specialist advice for people who are elderly and who have renal impairment. The loading dose of digoxin will need to be reduced.</strong></li></ul></li><li>The usual maintenance dose is 125 micrograms to 250 micrograms a day; this should be adjusted according to renal function, initial loading dose, and the heart rate response.</li><li>Check the person's pulse rate and heart rate no later than 1 week after initiation of treatment, and after any change in dose.</li><li>A more rapid response may be achieved by prescribing 750 micrograms to 1500 micrograms in divided doses over 24 hours. However, previous expert reviewers of this CKS topic suggest that usually no more than 1000 micrograms (1 mg) is needed in 24 hours. If a more rapid clinical response is required, consider referral to secondary care.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2019d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field d08809d9-6d92-4ee2-9059-6c423344da91 --><!-- end item dc9bf870-e369-4c76-8789-de0e97a0cc71 -->","subChapters":[]},{"id":"85e92612-2def-55eb-b6a1-fa8c6dff222a","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 2c7f6f25-cbd0-4559-9858-56b2837e3b09 --><h3>What are the adverse effects of digoxin?</h3><!-- end field 2c7f6f25-cbd0-4559-9858-56b2837e3b09 -->","summary":"","htmlStringContent":"<!-- begin item f144c7db-3291-4e2c-a35d-d70d2a35b86a --><!-- begin field da52a7b3-857f-4f67-85f5-28cb69ba60bc --><ul><li><strong>Cardiac adverse effects </strong>are the most serious adverse effects of digoxin and are usually associated with overdose. They include various conduction and rhythm disturbances, such as:<ul><li>Sinoatrial and atrioventricular block.</li><li>Premature ventricular contractions (resulting in bigeminy or trigeminy).</li><li>PR prolongation and ST-segment depression.</li></ul></li><li><strong>Non-cardiac adverse effects </strong>of digoxin include:<ul><li>Nausea, vomiting, and (less commonly) diarrhoea. Nausea, in particular, is indicative of overdose.</li><li>Visual abnormalities (blurred or yellow vision).</li><li>Central nervous system effects, such as weakness, dizziness, confusion, apathy, malaise, headache, depression, and psychosis.</li><li>Thrombocytopenia and agranulocytosis (rare).</li><li>Gynaecomastia in men following prolonged administration (digoxin has oestrogenic activity).</li></ul></li><li><strong>The adverse effects of digoxin are frequently due to its narrow therapeutic window. </strong>If significant adverse effects occur, <a class=\"topic-reference internal-reference\" href=\"/topics/atrial-fibrillation/prescribing-information/digoxin/#monitoring\">monitor</a> serum levels of digoxin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">McMurray et al, 2012</a>].</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2019d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field da52a7b3-857f-4f67-85f5-28cb69ba60bc --><!-- end item f144c7db-3291-4e2c-a35d-d70d2a35b86a -->","subChapters":[]},{"id":"01f5c7a0-aa9b-5529-b544-4027860c5138","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field 34cca551-64c9-4127-8c4c-bb31845e6cea --><h3>How should I monitor someone taking digoxin?</h3><!-- end field 34cca551-64c9-4127-8c4c-bb31845e6cea -->","summary":"","htmlStringContent":"<!-- begin item 46d415ad-b28b-41ff-82b1-519a1cee3947 --><!-- begin field 5806790e-68f1-426e-9546-8082776320b7 --><ul><li><strong>Routine monitoring of serum digoxin is not recommended </strong>because there is no evidence from randomized controlled trials to indicate that regular monitoring confers better outcomes.</li><li><strong>Consider checking serum digoxin levels if:</strong><ul><li>The person experiences adverse effects suggestive of toxicity (such as confusion, nausea, anorexia, or disturbance of colour vision).</li><li>Other factors may affect the serum digoxin level, such as the use of a concomitant drug (for example amiodarone, diltiazem, or verapamil), deteriorating renal function, thyroid disease, and advancing age.</li><li>Poor adherence is suspected.</li></ul></li><li><strong>Digoxin toxicity can occur even when the serum digoxin concentration is within the therapeutic range (between 0.7 nanograms/mL and 2.0 nanograms/mL); </strong>always interpret results in the clinical context.<ul><li>Take blood samples at least 6 hours after the previous dose, but ideally 8–12 hours afterwards.</li><li>Monitor digoxin levels several days after the last dose change.</li></ul></li><li><strong>The likelihood of toxicity </strong><strong>depends on the serum concentration of digoxin.</strong><ul><li>Levels less than 1.5 nanograms/mL in the absence of hypokalaemia indicate that digoxin toxicity is unlikely.</li><li>Levels greater than 3.0 nanograms/mL indicate that digoxin toxicity is likely.</li><li>With levels between 1.5 nanograms/mL and 3.0 nanograms/mL, digoxin toxicity should be considered a possibility.</li></ul></li><li><strong>In addition, check blood chemistry </strong>(electrolytes, urea, and creatinine) at least annually (more frequently in elderly people and people with renal impairment).<ul><li>These tests will often be done routinely, as renal function is likely to be monitored owing to the use of nephrotoxic drugs (such as diuretics and drugs affecting the renin-angiotensin system).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">National Clinical Guideline Centre for Acute and Chronic Conditions, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2019d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 5806790e-68f1-426e-9546-8082776320b7 --><!-- end item 46d415ad-b28b-41ff-82b1-519a1cee3947 -->","subChapters":[]},{"id":"8c70799f-543e-5df6-83e8-76c7fbbc38a0","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field d30c5201-e34e-4758-829f-5b7916102673 --><h3>What key drug interactions should I be aware of for digoxin?</h3><!-- end field d30c5201-e34e-4758-829f-5b7916102673 -->","summary":"","htmlStringContent":"<!-- begin item 40ceb03b-7c76-407e-9e23-43bc75f2c686 --><!-- begin field ca3d4e6f-b40c-4c4d-ab69-770c9c37c7aa --><p><strong>Key Drug interactions with digoxin include:</strong></p><ul><li><strong>Antidepressants</strong><ul><li>Avoid tricyclic antidepressants with digoxin as they are possibly proarrhythmic in cardiac disease. Consider selective serotonin reuptake inhibitors (SSRIs) or mirtazapine instead.</li><li>Avoid venlafaxine with digoxin in people at risk of arrhythmias. Consider SSRIs or mirtazapine instead.</li><li>Avoid trazodone with digoxin because it increases digoxin plasma levels. Consider SSRIs or mirtazapine instead.</li></ul></li><li><strong>Beta-blockers</strong><ul><li>Concomitant administration of a beta-blocker and digoxin can reduce heart rate and prolong atrioventricular (AV) conduction time, increasing the risk of AV block and bradycardia. Monitor pulse carefully.</li><li>An increase in plasma digoxin levels has been noted with carvedilol. Monitor for signs of digoxin toxicity (confusion, anorexia, nausea, and disturbance of colour vision) when starting, adjusting, or stopping carvedilol.</li></ul></li><li><strong>Buproprion </strong>— co-administration of buproprion with digoxin may decrease digoxin levels. Digoxin levels may rise on discontinuation of bupropion, people taking buproprion and digoxin should be monitored for possible digoxin toxicity when buproprion is discontinued. </li><li><strong>Diuretics, acetazolamide, and amphotericin</strong><ul><li>Increased cardiac toxicity with digoxin if hypokalaemia occurs with these drugs. Monitor digoxin levels and adjust dose accordingly.</li></ul></li><li><strong>St John's wort</strong><ul><li>The plasma concentration of digoxin may be reduced by St John's wort. Advise people taking digoxin that they should not use St John's wort and that they should check with their pharmacist before using any other over-the-counter medications.</li></ul></li><li><strong>Proton pump inhibitors </strong>— the manufacturer's SPC advise the co-administration of proton pump inhibitors (particularly omeprazole) causes increasing plasma levels of digoxin. Similar effects have been reported with pantoprazole and rabeprazole to a lesser extent. the manufacturer advises caution in co-prescribing these drugs.  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2020b</a>]</li><li><strong>Monitor for signs and symptoms of <a class=\"topic-reference internal-reference\" href=\"/topics/atrial-fibrillation/prescribing-information/digoxin/#adverse-effects\">digoxin toxicity</a></strong><strong> (and adjust doses accordingly) if digoxin is given with the following drugs, which may increase plasma concentration of digoxin:</strong><ul><li>Amiodarone.</li><li>Antimicrobials (itraconazole, macrolide antibiotics, tetracycline, and trimethoprim).</li><li>Calcium-channel blockers (diltiazem, verapamil, and possibly nifedipine). There is also an increased risk of AV block and bradycardia with verapamil.</li><li>Chloroquine and hydroxychloroquine.</li><li>Spironolactone.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2019d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field ca3d4e6f-b40c-4c4d-ab69-770c9c37c7aa --><!-- end item 40ceb03b-7c76-407e-9e23-43bc75f2c686 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}